Literature DB >> 18367637

B-type natriuretic peptide decreases gastric emptying and absorption.

Anteneh Addisu1, William R Gower, Carol S Landon, John R Dietz.   

Abstract

Natriuretic peptides have been shown to decrease contractility of isolated gastric smooth muscle cells. However there is a paucity of research showing whether this effect has functional significance in the whole animal. The objective of this study was to test whether intravenously administered B-type Natriuretic Peptide (BNP) has an effect on gastric emptying and/or absorption in a whole animal mouse model. C57BL/6-Wild-type (WT) and Natriuretic Peptide Receptor type A (NPR-A) knockout (KO) mice were used in these studies. Gastric contractility was examined in anesthetized mice before and after BNP vs. vehicle injection. Gastric emptying of gavage fed 70 Kilo Dalton (kDa) FITC-dextran and absorption of 4 kDa FITC-dextran were compared in BNP vs. vehicle treated conscious WT and KO mice. BNP decreased gastric contractility (measured in change in intragastric pressure) from 2.26 +/- 0.29 to 1.44 +/- 0.11 mmHg (P < 0.05), pressure returned to 2.08 +/- 0.17 after 5 BNP half-lives (P < 0.05). There was no significant change in the vehicle or KO. BNP also decreased gastric emptying in WT mice compared to vehicle, 87.8 +/- 0.8% vs. 97.3 +/- 1.04% (P < 0.05) and this effect showed a dose-response relationship. In KO mice emptying was 95.8 +/- 0.5% (BNP) vs. 91.7 +/- 0.7% (Vehicle) (P > 0.05). The absorption in WT mice was 28.2 +/- 7.8 (relative fluorescence units) for BNP vs. 91 +/- 25.9 for vehicle (P < 0.05). For KO mice absorption was 64.3 +/- 14.9 for BNP vs. 60.6 +/- 17.4 for vehicle (P > 0.05). The results show that BNP decreases intragastric pressure, emptying and absorption by acting via the NPR-A receptor. We postulate that this effect is aimed at decreasing preload through decreased water and electrolyte absorption from the GI tract and may also be responsible for the symptoms of impaired gastrointestinal function observed in heart failure patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367637     DOI: 10.3181/0708-RM-216

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  9 in total

1.  Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?

Authors:  Rafael de la Espriella-Juan; Juan Sanchis; Antoni Bayés-Genís; Julio Núñez
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

Review 2.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

3.  A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community.

Authors:  Valentina Cannone; Guido Boerrigter; Alessandro Cataliotti; Lisa C Costello-Boerrigter; Timothy M Olson; Paul M McKie; Denise M Heublein; Brian D Lahr; Kent R Bailey; Maurizio Averna; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

4.  A new role for the natriuretic peptides: metabolic regulators of the adipocyte.

Authors:  Lisa C Costello-Boerrigter; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2009-06-02       Impact factor: 24.094

Review 5.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

6.  Cardiac natriuretic peptides: contributors to cardiac cachexia or possible anti-obesity agents or both?

Authors:  Lisa C Costello-Boerrigter
Journal:  Diabetes       Date:  2012-10       Impact factor: 9.461

Review 7.  Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure.

Authors:  Kun Ding; Yang Gui; Xu Hou; Lifang Ye; Lihong Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-26

8.  Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure.

Authors:  Huai-Ren Chang; Jen-Che Hsieh; Bang-Gee Hsu; Ling-Yi Wang; Michael Yu-Chih Chen; Ji-Hung Wang
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

Review 9.  The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.

Authors:  Alessandro Bellis; Ciro Mauro; Emanuele Barbato; Giuseppe Di Gioia; Daniela Sorriento; Bruno Trimarco; Carmine Morisco
Journal:  Cells       Date:  2020-09-21       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.